Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC. The clinical study enrolled 750 patients in over 150 sites worldwide.
“We are very pleased to have achieved this important milestone for Artisan and expect to report the results later this year”
"DIC in sepsis is a severe condition with a very poor prognosis for patients," stated Dr. Inder Kaul, M.D., M.P.H., Chief Medical Officer of Artisan Pharma. "We are energized at having reached this milestone and now will be focusing on preparing to analyze the results, which are highly anticipated by the medical and scientific communities."
"We are very pleased to have achieved this important milestone for Artisan and expect to report the results later this year," commented Dr. Gary T. Shearman, Executive Chairman.
SOURCE Artisan Pharma, Inc.
MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test